Table S1.
Baseline characteristics of the 12 patients with HCV-associated HCC or non-HCC cirrhosis
| Characteristic | HCC | Non-HCC cirrhosis |
| Patients, n | 8 | 4 |
| Age, y, mean ± SEM | 55 ± 3 | 51 ± 3 |
| Male sex, n (%) | 7 (87.5) | 4 (100) |
| Alanine aminotransferase, U/L, mean ± SEM* | 105 ± 13 | 76 ± 12 |
| Aspartate aminotransferase, U/L, mean ± SEM† | 102 ± 19 | 100 ± 15 |
| γ-Glutamyltransferase, U/L, mean ± SEM‡ | 133 ± 41 | 70 ± 18 |
| Prothombin time, INR, mean ± SEM§ | 1.2 ± 0.1 | 1.6 ± 0.1 |
| Total bilirubin, mg/dL, mean ± SEM¶ | 2.6 ± 0.7 | 1.9 ± 0.1 |
| Platelets (103/µL), mean ± SEM# | 148.5 ± 39.4 | 65.7 ± 16.0 |
| α-Fetoprotein, ng/mg, mean ± SEM‖ | 297 ± 240 | 59 ± 35 |
| Serum HCV RNA, log10 IU/mL, mean ± SEM | 5.9 ± 0.2 | 5.7 ± 0.4 |
| HCV genotype, n | ||
| 1a | 1 | 3 |
| 1b | 6 | 1 |
| 2a/2c | 1 | 0 |
| Liver pathology | ||
| Nontumorous tissue** | ||
| Activity grade, mean ± SEM | 7.4 ± 0.9 | 5.4 ± 0.5 |
| Fibrosis stage, mean ± SEM | 5.8 ± 0.2 | 6.0 ± 0.0 |
| F5, n | 2 | 0 |
| F6, n | 6 | 4 |
| Tumor grade, n†† | ||
| G2 | 4 | |
| G3 | 4 | |
| Tumor size, n | ||
| ≥2 and ≤3 cm | 4 | |
| >3 cm | 4 | |
*
Normal range, ≤43 U/L.
†
Normal range, ≤42 U/L.
‡
Normal range, ≤38 U/L.
§
Normal range, 0.80–1.20 INR.
¶
To convert serum bilirubin values to micromoles per liter, multiply by 17.1.
#
Normal values, ≥159 to ≤388 (103/μL).
‖
Normal range, <10.0 ng/mL.
**
The degree of activity and stage of fibrosis were assessed according to the Ishak scoring system (45).
††
Tumors were graded using the Edmondson–Steiner grading system (46).